Korro Bio, Inc. is trading at $11.85 (+7.27%) in pre-market. - Jones Trading upgraded Korro Bio to Buy with a price target of $23.00 after reporting promising preclinical data for its RNA editing platform. - H.C. Wainwright maintained a Buy rating, adjusting its price target to $15.00. - The positive analyst sentiment and preclinical data serve as strong catalysts driving the stock higher.